Liraglutide Increases FGF-21 Activity and Insulin Sensitivity in High Fat Diet and Adiponectin Knockdown Induced Insulin Resistance

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Yang, Mengliu ^a   Zhang, Lili ^a   Wang, Chong ^a   Liu, Hua ^b   Boden, Guenther ^c   Yang, Gangyi ^a   Li, Ling ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADIPONECTIN; APOLIPOPROTEIN E; BETA KLOTHO PROTEIN; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KLOTHO PROTEIN; LIRAGLUTIDE; MESSENGER RNA; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE METABOLISM; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPID DIET; LIVER; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; APOLIPOPROTEINS E; BLOOD GLUCOSE; DIET, HIGH-FAT; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, KNOCKOUT; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA INTERFERENCE; RNA, MESSENGER;

ADENOVIRIDAE; ANIMALIA; MUS;

EID: 84869051421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048392     Document Type: Article

References (33)

1. Holst JJ, (1994) Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107: 1848-55.
2. Kreymann B, Williams G, Ghatei MA, Bloom SR, (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-4.
3. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, et al. (1997) Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99: 2883-9.
4. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, et al. (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-408.
5. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, et al. (2004) Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 47: 806-15.
6. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, et al. (2003) Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144: 5149-58.
7. Vilsboll T, Krarup T, Madsbad S, Holst JJ, (2002) Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia 45: 1111-9.
8. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, et al. (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-4.
9. Rachman J, Barrow BA, Levy JC, Turner RC, (1997) Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-11.
10. Zander M, Madsbad S, Madsen JL, Holst JJ, (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359: 824-30.
11. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, et al. (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 330: 577-84.
12. Rütti S, (2009) Liraglutide induces human betacell proliferation, counteracts low density lipoprotein anti-proliferative effects and protects from IL-1B induced apoptosis. Diabetes 58 (Suppl 1): 1592-P.
13. Li L Yang G, Li Q, Tan X, Liu H, et al. (2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 10: 921-30.
14. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-35.
15. Chen WW, Li L, Yang GY, Li K, Qi XY, et al. (2008) Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116: 65-8.
16. Li L, Yang G, Ning H, Yang M, Liu H, et al. (2008) Plasma FGF-21 levels in type 2 diabetic patients with ketosis. Diabetes Res Clin Pract 82: 209-13.
17. Li K, Li L, Yang M, Zong H, Liu H, et al. (2009) Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. Eur J Endocrinol 161: 391-5.
18. Boden G, (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3-10.
19. Unger RH, (1995) Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44: 863-70.
20. Breslow JL, (1996) Mouse models of atherosclerosis. Science 272: 685-8.
21. Zhang SH, Reddick RL, Piedrahita JA, Maeda N, (1992) Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-71.
22. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, et al. (2007) Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115: 1275-84.
23. Chen Y, Yang G, Li L, Li K, Chen W, (2009) The changes of glucose-lipid metabolism in ApoE-/- mice with high-fat induced insulin resistance. Chin J Diabetes 17: 590-2.
24. To AW, Ribe EM, Chuang TT, Schroeder JE, Lovestone S, (2011) The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. PLoS One 6: e16991.
25. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, et al. (2002) Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8: 731-7.
26. Li L, Yang G, Shi S, Yang M, Liu H, et al. (2009) The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-alpha (TNF-alpha) in vivo. Cytokine 45: 12-9.
27. Li K, Li L, Yang GY, Liu H, Li SB, et al. (2010) Effect of short hairpin RNA-mediated adiponectin/Acrp30 down-regulation on insulin signaling and glucose uptake in the 3T3-L1 adipocytes. J Endocrinol Invest 33: 96-102.
28. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86: 1930-5.
29. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, et al. (2009) Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 32: 1542-6.
30. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-81.
31. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
32. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
33. Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, et al. (1995) Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1: 1311-131.